Análisis de la eliminación de detritus urinario de pacientes con cáncer, tratados con virus oncolítico Wt1-5.
| dc.contributor.advisor | Ayala Fajardo, Adis | |
| dc.contributor.advisor | Guerrero Fonseca , Carlos Arturo | |
| dc.contributor.author | Guarín Molina , Leidy Mariana | |
| dc.date.accessioned | 2025-12-02T17:48:05Z | |
| dc.date.available | 2025-12-02T17:48:05Z | |
| dc.date.created | 2025-09-03 | |
| dc.description | La viroterapia oncolítica ha surgido como una estrategia prometedora en la investigación contra el cáncer. En este estudio, se evaluó la eliminación del virus oncolítico Wt1-5 en la orina de 5 pacientes con diferentes tipos de cáncer tratados con este virus, mediante la detección de proteínas virales así como su capacidad para infectar células U937 en cultivo. Para ello, se recolectaron muestras de orina en diferentes tiempos post-aplicación (24-504 h), analizándose la presencia de partículas virales mediante SDS-PAGE, Western Blot, inmunofluorescencia, citometría de flujo y ELISA de captura. Se determinó la presencia de proteínas virales en detritus urinario, indicando la excreción del virus por esta vía. Además, se observó que parte del virus eliminado mantiene su capacidad infectiva, al lograr la infección de células U937 in vitro. Los resultados mostraron que la mayor cantidad de partículas virales en orina se detectó entre las 24-96 horas post-aplicación, con una reducción progresiva a partir de las 72 horas, completándose la eliminación en aproximadamente 21 días. La inmunofluorescencia y la citometría de flujo evidenciaron variaciones en la infección celular según el tiempo de recolección de la orina, sugiriendo una eliminación viral dinámica. El ELISA de captura sugiere la presencia de proteínas virales libres, indicando que parte del virus es eliminado en forma de fragmentos no infecciosos. Se concluye que el virus oncolítico Wt1-5 se excreta en la orina y que parte de él conserva su capacidad infectiva, lo que sugiere la necesidad de evaluar su eliminación y persistencia en fluidos biológicos. | |
| dc.description.abstract | Oncolytic virotherapy has emerged as a promising strategy in cancer research. In this study, the elimination of the oncolytic virus Wt1-5 in the urine of five cancer patients treated with this virus was evaluated by detecting viral proteins and assessing its ability to infect U937 cells in culture. Urine samples were collected at different post-application times (24–504 h), and the presence of viral particles was analyzed through SDS-PAGE, Western Blot, immunofluorescence, flow cytometry, and capture ELISA. Viral proteins were detected in urinary debris, indicating virus excretion through this route. Additionally, part of the eliminated virus retained its infective capacity, as it successfully infected U937 cells in vitro. Results showed that the highest amount of viral particles in urine occurred between 24–96 hours post-application, with a progressive reduction starting at 72 hours, and complete elimination at approximately 21 days. Immunofluorescence and flow cytometry revealed variations in cellular infection depending on urine collection time, suggesting dynamic viral shedding. The capture ELISA indicated the presence of free viral proteins, suggesting that part of the virus is eliminated as non-infectious fragments. It is concluded that the oncolytic virus Wt1-5 is excreted in urine and that part of it retains infective capacity, highlighting the need to evaluate its elimination and persistence in biological fluids. | |
| dc.description.sponsorship | Universidad Nacional de Colombia | |
| dc.format.mimetype | ||
| dc.identifier.uri | http://hdl.handle.net/11349/100021 | |
| dc.language.iso | spa | |
| dc.publisher | Universidad Distrital Francisco José de Caldas | |
| dc.relation.references | Guerrero CA, Pardo P, Rodriguez V, Guerrero R, Acosta O. Inhibition of rotavirus ECwt infection in ICR suckling mice by N-acetylcysteine, peroxisome proliferator-activated receptor gamma agonists and cyclooxygenase-2 inhibitors. Mem Inst Oswaldo Cruz. 2013;108(6):741- 754. doi:10.1590/0074-0276108062013011 | |
| dc.relation.references | Guerrero M, Hernández J, Gomez L, Guerrero C. Oxidative stress enhances rotavirus oncolysis in breast cancer and leukemia, except in melanoma with abundant matrix. Virus Res. 2024;339. doi:10.1016/j.virusres.2023.199285 | |
| dc.relation.references | Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(1):86-103. | |
| dc.relation.references | Organización Mundial de la Salud (OMS). (2024). Cancer: Key facts. Organización Mundial de la Salud. https://www.who.int/news-room/fact-sheets/detail/cancer | |
| dc.relation.references | Siegel, R. L., Miller, K. D., & Fuchs, H. E. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48. https://doi.org/10.3322/caac.21763 | |
| dc.relation.references | Russell, S. J., Peng, K. W., & Bell, J. C. (2019). Oncolytic virotherapy. Nature Biotechnology, 37(1), 39–51. https://doi.org/10.1038/s41587-018-0110 | |
| dc.relation.references | Guerrero, C., & Acosta, C. (2021). Evaluación del potencial oncolítico del rotavirus Wt1-5 en líneas celulares tumorales humanas. Grupo de Biología Molecular de Virus, Universidad Nacional de Colombia. | |
| dc.relation.references | Aref S, Bailey K, Fielding A. Measles to the rescue: A review of oncolytic measles virus. Viruses. 2016;8(10):294. doi:10.3390/v8100294 | |
| dc.relation.references | Howells A, Marelli G, Lemoine NR, Wang Y. Oncolytic viruses: Interaction of virus and tumor cells in the battle to eliminate cancer. Front Oncol. 2017;7:195. doi:10.3389/fonc.2017.00195 | |
| dc.relation.references | Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-662. doi:10.1038/nrd4663 | |
| dc.relation.references | Abbas, A. K., Lichtman, A. H., & Pillai, S. (2018). Cellular and Molecular Immunology. 9th ed. Elsevier. | |
| dc.relation.references | Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2018). Functions of natural killer cells. Nature Immunology, 9(5), 503-510. | |
| dc.relation.references | Crotty, S., & Ahmed, R. (2004). Immunological memory in humans. Seminars in Immunology, 16(3), 197-203. | |
| dc.relation.references | Chen, D. S., & Mellman, I. (2017). Elements of cancer immunity and the cancer–immune set point. Nature, 541(7637), 321-330. | |
| dc.relation.references | Ramig RF. Pathogenesis of intestinal and systemic rotavirus infection. J Virol. 2004;78(19):10213-10220. doi:10.1128/jvi.78.19.10213-10220.2004 | |
| dc.relation.references | Amino JO, Raev SA, Chepngeno J, Mainga AO, Guo Y, SaifRotavirus interactions with host intestinal epithelial cells. Front Immunol. 2021;12:793841. doi:10.3389/fimmu.2021.793841 | |
| dc.relation.references | Desselberger U. Rotaviruses. Virus Res. 2014;190:75-96. doi:10.1016/j.virusres.2014.06.016 | |
| dc.relation.references | Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiologia: el sistema immunitario en la salud y la enfermedad. 7ª ed. Barcelona: Editorial Médica Panamericana; 2008. | |
| dc.relation.references | Arias CF, López S. Rotavirus cell entry: not so simple after all. Curr Opin Virol. 2021;48:42-48. doi:10.1016/j.coviro.2021.03.011 | |
| dc.relation.references | Rico J, Perez C, Guerrero R, Hernandez J, Guerrero C, Acosta O. Implication of heat shock proteins in rotavirus entry into Reh cells. Acta Virol. 2020;64(4):433-450. doi:10.4149/av_2020_406 | |
| dc.relation.references | Santana AY, Guerrero CA, Acosta O. Implication of Hsc70, PDI and integrin αvβ3 involvement during entry of the murine rotavirus ECwt into small-intestinal villi of suckling mice. Arch Virol. 2013;158(6):1323-1336. doi:10.1007/s00705-013-1626-6 | |
| dc.relation.references | Rico J, Perez C, Hernandez J, Guerrero C, Acosta O. Cell surface heat shock protein mediated entry of tumor cell-adapted rotavirus into U-937 cells. Folia Microbiol (Praha). 2021;66(4):623- 638. doi:10.1007/s12223-020-00845-x | |
| dc.relation.references | Jiang L, Tang A, Song L, Tong Y, Fan H. Advances in the development of antivirals for rotavirus infection. Front Immunol. 2023;14:1041149. doi:10.3389/fimmu.2023.1041149 | |
| dc.relation.references | Smith A, Liu B. Urinary Protein Analysis Techniques. In: *Urinary Biomarkers: Methods and Protocols*. Springer; 2021:145-160. doi:10.1007/978-3-030-71186-7_5 | |
| dc.relation.references | Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642-662. doi:10.1038/nrd4663. | |
| dc.relation.references | Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016;107(10):1373-1379. doi:10.1111/cas.13027. | |
| dc.relation.references | Comins C, Heinemann L, Harrington K, et al. Reovirus (Reolysin) in cancer therapy: urinary excretion reflects systemic delivery. Cancer Gene Ther. 2010;17(1):42-50. doi:10.1038/cgt.2009.48. | |
| dc.relation.references | Smith A, Liu B. Urinary Biomarkers: Methods and Protocols. 2nd ed. Springer; 2021. | |
| dc.relation.references | Guerrero CA, Guerrero RA, Silva E, Acosta O, Barreto E. (2016). Experimental adaptation of rotaviruses to tumor cell lines. PLoS One. 11(2):e0147666. | |
| dc.relation.references | Rodríguez LE, Guerrero CA. (2006). La proteína viral VP6 de rotavirus coinmonoprecipita con HSC70 en células MA104. Rev Fac Med Univ Nac Colomb. 54(1):29. | |
| dc.relation.references | Guerrero RA, Guerrero CA, Guzmán F, Acosta O. Assessing the oncolytic potential of rotavirus on mouse myeloma cell line Sp2/0-Ag14. Biomédica. 2020;40 (2). | |
| dc.rights.acceso | Abierto (Texto Completo) | |
| dc.rights.accessrights | OpenAccess | |
| dc.subject | Viroterapia oncolítica | |
| dc.subject | Virus Wt1-5 | |
| dc.subject | Excreción viral | |
| dc.subject | Proteínas Virales | |
| dc.subject | Infección in vitro | |
| dc.subject | Citometría de flujo | |
| dc.subject.keyword | Wt1-5 virus | |
| dc.subject.keyword | Viral excretion | |
| dc.subject.keyword | Viral Proteins | |
| dc.subject.keyword | In Vitro infection | |
| dc.subject.keyword | Flow cytometry | |
| dc.subject.lemb | Licenciatura en Química -- Tesis y disertaciones académicas | |
| dc.subject.lemb | Terapia de gen | |
| dc.subject.lemb | Cáncer -- Tumores | |
| dc.subject.lemb | Excreción | |
| dc.subject.lemb | Orina -- Análisis | |
| dc.title | Análisis de la eliminación de detritus urinario de pacientes con cáncer, tratados con virus oncolítico Wt1-5. | |
| dc.title.titleenglish | Analysis of the elimination of urinary debris from cancer patients treated with the oncolytic virus Wt1-5. | |
| dc.type | bachelorThesis | |
| dc.type.coar | http://purl.org/coar/resource_type/c_7a1f | |
| dc.type.degree | Investigación-Innovación | |
| dc.type.driver | info:eu-repo/semantics/bachelorThesis |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 7 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: